Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment

被引:0
作者
Chin-King Looi
Felicia Fei-Lei Chung
Chee-Onn Leong
Shew-Fung Wong
Rozita Rosli
Chun-Wai Mai
机构
[1] International Medical University,School of Postgraduate Studies
[2] World Health Organization,Mechanisms of Carcinogenesis Section (MCA), Epigenetics Group (EGE) International Agency for Research on Cancer
[3] International Medical University,School of Pharmacy
[4] International Medical University,Center for Cancer and Stem Cell Research, Institute for Research, Development and Innovation (IRDI)
[5] International Medical University,School of Medicine
[6] Universiti Putra Malaysia,UPM
来源
Journal of Experimental & Clinical Cancer Research | / 38卷
关键词
Pancreatic cancer; Immunotherapy; Tumor microenvironment;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 950 条
[1]  
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[2]  
Ferlay J(2016)Epidemiology of pancreatic cancer World J Gastroenterol 22 9694-9705
[3]  
Soerjomataram I(2014)Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Cancer Res 74 2913-2921
[4]  
Siegel RL(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403-2413
[5]  
Torre LA(2012)Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol 18 4944-4958
[6]  
Jemal A(2011)FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 1817-1825
[7]  
Ilic M(2013)Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 1691-1703
[8]  
Ilic I(2012)Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2443-2454
[9]  
Rahib L(2014)Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32 1020-1030
[10]  
Smith BD(2015)PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma N Engl J Med 372 311-319